Recruitment of participants to a multiple sclerosis trial: the CombiRx experience

scientific article published on April 2014

Recruitment of participants to a multiple sclerosis trial: the CombiRx experience is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1177/1740774513517184
P932PMC publication ID3972629
P698PubMed publication ID24686106

P50authorGary R. CutterQ89543066
P2093author name stringMinal J Bhanushali
Stacey S Cofield
Fred D Lublin
Jerry S Wolinsky
Robin A Conwit
Steve Powell
Tarah Gustafson
P2860cites workRecruitment of participants to a clinical trial of botanical therapy for benign prostatic hyperplasiaQ30427093
The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and baseline characteristicsQ30932853
Seasonal prevalence of MS disease activityQ34125522
Clinical trial performance of community- vs university-based practices in the submacular surgery trials (SST): SST report no. 2.Q34130221
Recruitment and retention of patients into emergency medicine clinical trialsQ34681587
Randomized study combining interferon and glatiramer acetate in multiple sclerosisQ36780801
Clinical trials: the challenge of recruitment and retention of participants.Q37760546
Strategies for recruitment and retention of participants in clinical trialsQ82210667
P433issue2
P407language of work or nameEnglishQ1860
P921main subjectmultiple sclerosisQ8277
P304page(s)159-166
P577publication date2014-04-01
P1433published inClinical TrialsQ5133802
P1476titleRecruitment of participants to a multiple sclerosis trial: the CombiRx experience
P478volume11

Reverse relations

cites work (P2860)
Q34820877An evaluation of recruitment methods utilized for a clinical trial with periodontal and diabetes enrollment criteria: the Diabetes and Periodontal Therapy Trial
Q47967971Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years.
Q90585642Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical Trials

Search more.